Restricted accessResearch articleFirst published online 2025
Efficacy and safety of pharmacological and non-pharmacological interventions for antipsychotic-induced weight gain in individuals with schizophrenia: A systematic review and network meta-analysis of 55 clinical trials
Schizophrenia is a severe mental disorder that impacts thoughts, emotions, and behavior, affecting 0.32% of the global population. While antipsychotic medications are crucial for managing symptoms, nearly half of individuals with schizophrenia experience weight gain, leading to treatment non-compliance and further health complications. Our systematic review and network meta-analysis aim to provide comprehensive evidence on the safety and efficacy of pharmacological and non-pharmacological interventions for antipsychotic-induced weight gain.
Methods:
We conducted this study in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, following our protocol (CRD42024599597). We searched PubMed, Scopus, Web of Science, and Cochrane Library until July 2025. Only randomized placebo-controlled trials were included. We focused on anthropometric measurements and safety profiles. The primary outcome was weight change, while the secondary outcomes included waist-hip ratio, waist circumference, and hip circumference.
Result:
Fifty-five studies were included in the meta-analysis, with a total of 2977 individuals. Regarding the weight change, the highest three interventions hold the highest probability of being the most effective therapy in weight loss compared to the Usual care group were Semagultide (MD: −13.5 [−17.3, −9.57], followed by Metformin + NutriEx (MD: −6.34, [−9.85, −2.9]), then Nizatidine (MD: −5.46 [−7.77, −2.76]). According to non-pharmacological interventions, all interventions showed significant reductions in weight (p-value < 0.05).
Conclusion:
We found that Semaglutide has the highest probability of being the most effective therapy in the reduction of weight gain and BMI. Liraglutide was associated with mild adverse effects. Additional trials focusing on non-pharmacological approaches are essential.
AgarwalSMStogiosNAhsanZA, et al. (2022) Pharmacological interventions for prevention of weight gain in people with schizophrenia. Cochrane Database of Systematic Reviews10(10): CD013337.
2.
AllisonDBMentoreJLHeoM, et al. (1999) Antipsychotic-induced weight gain: A comprehensive research synthesis. The American Journal of Psychiatry156(11): 1686–1696.
3.
AltmanDGBlandJM (2005) Standard deviations and standard errors. BMJ (Clinical Research Ed.)331(7521): 903.
4.
Alvarez-JiménezMHetrickSEGonzález-BlanchC, et al. (2008) Non-pharmacological management of antipsychotic-induced weight gain: Systematic review and meta-analysis of randomised controlled trials. The British Journal of Psychiatry193(2): 101–107.
5.
AssunçãoSSMRuschelSIde Cássia Rodrigues Rosal, et al. (2006) Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine. Revista Brasileira de Psiquiatria28(4): 270–276.
6.
AtmacaMKulogluMTezcanE, et al. (2003) Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. Human Psychopharmacology18(6): 457–461.
7.
AtmacaMKulogluMTezcanE, et al. (2004) Nizatidine for the treatment of patients with quetiapine-induced weight gain. Human Psychopharmacology19(1): 37–40.
8.
BakMCampfortsBDomenP, et al. (2024) Glucagon-like peptide agonists for weight management in antipsychotic-induced weight gain: A systematic review and meta-analysis. Acta Psychiatrica Scandinavica150(6): 516–529.
9.
BaptistaTMartínezJLacruzA, et al. (2006) Metformin for prevention of weight gain and insulin resistance with olanzapine: A double-blind placebo-controlled trial. Canadian Journal of Psychiatry51(3): 192–196.
10.
BaptistaTRangelNFernándezV, et al. (2007) Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: A multicentric, double-blind, placebo-controlled trial. Schizophrenia Research93(1–3): 99–108.
11.
BaptistaTRangelNEl FakihY, et al. (2009) Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: A pilot double-blind, placebo-controlled, 12-week trial. Pharmacopsychiatry42(1): 14–19.
12.
Barnard-KellyKWhicherCAPriceHC, et al. (2022) Liraglutide and the management of overweight and obesity in people with severe mental illness: Qualitative sub-study. BMC Psychiatry22(1): 21.
13.
BiedermannFFleischhackerWWKemmlerG, et al. (2014) Sibutramine in the treatment of antipsychotic-induced weight gain: A pilot study in patients with schizophrenia. International Clinical Psychopharmacology29(3): 181–184.
14.
BitterI (2020) Definitions and measurement of negative symptoms in schizophrenia. In: BitterI (ed.) Managing negative symptoms of schizophrenia. Oxford University Press, pp. 1–18.
15.
BorovickaMCFullerMAKonickiPE, et al. (2002) Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. The Journal of Clinical Psychiatry63(4): 345–348.
16.
BrarJSGanguliRPandinaG, et al. (2005) Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. The Journal of Clinical Psychiatry66(2): 205–212.
17.
BustilloJRLaurielloJParkerK, et al. (2003) Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacology28(3): 527–529.
18.
CarliMKolachalamSLongoniB, et al. (2021) Atypical antipsychotics and metabolic syndrome: From molecular mechanisms to clinical differences. Pharmaceuticals (Basel, Switzerland)14(3): 238.
19.
CarrizoEFernándezVConnellL, et al. (2009) Extended release metformin for metabolic control assistance during prolonged clozapine administration: A 14 week, double-blind, parallel group, placebo-controlled study. Schizophrenia Research113(1): 19–26.
20.
CastleDJBuckleyPFGaughranFP (2017) Effects of Antipsychotic Medications on Physical Health. Oxford University Press.
21.
ChanMQinZManSC, et al. (2022) Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: A randomized controlled trial. Psychiatry and Clinical Neurosciences76(3): 77–85.
22.
CharlsonFJFerrariAJSantomauroDF, et al. (2018) Global epidemiology and burden of schizophrenia: Findings from the global burden of disease study 2016. Schizophrenia Bulletin44(6): 1195–1203.
23.
ChiuC-CLuMLHuangMC, et al. (2016) Effects of low dose metformin on metabolic traits in clozapine-treated schizophrenia patients: An exploratory twelve-week randomized, double-blind, placebo-controlled study. PLoS One11(12): e0168347.
ConnollyMKellyC (2005) Lifestyle and physical health in schizophrenia. Advances in Psychiatric Treatment11(2): 125–132.
26.
DeberdtWWinokurACavazzoniPA, et al. (2005) Amantadine for weight gain associated with olanzapine treatment. European Neuropsychopharmacology15(1): 13–21.
27.
DeRSmithECCNavagnanavelJ, et al. (2025) The impact of weight gain on antipsychotic nonadherence or discontinuation: A systematic review and meta-analysis. Acta Psychiatrica Scandinavica151(2): 109–126.
28.
de SilvaVADayabandaraMWijesundaraH, et al. (2015) Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study. Journal of Psychopharmacology29(12): 1255–1261.
29.
de SilvaVASuraweeraCRatnatungaSS, et al. (2016) Metformin in prevention and treatment of antipsychotic induced weight gain: A systematic review and meta-analysis. BMC Psychiatry16(1): 341.
30.
FitzgeraldIO’ConnellJKeatingD, et al. (2022) Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: Development of the first evidence-based guideline using GRADE methodology. Evidence-Based Mental Health25(1): 15–22.
31.
ForetzMGuigasBViolletB (2023) Metformin: Update on mechanisms of action and repurposing potential. Nature Reviews. Endocrinology19(8): 460–476.
32.
GoffDKreyenbuhlJ (2012) Assessing adherence to antipsychotic medications. In KeefeR (ed.) Guide to Assessment Scales in Schizophrenia. Springer Healthcare UK, pp. 65–71.
33.
GordonPCXavierJCLouzãMR (2013) Weight gain, metabolic disturbances, and physical health care in a Brazilian sample of outpatients with schizophrenia. Neuropsychiatric Disease and Treatment9: 133–138.
34.
GrahamKAGuHLiebermanJA, et al. (2005) Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. The American Journal of Psychiatry162(9): 1744–1746.
35.
HendersonDCCopelandPMDaleyTB, et al. (2005) A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. The American Journal of Psychiatry162(5): 954–962.
36.
HendersonDCFanXCopelandPM, et al. (2007) A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatrica Scandinavica115(2): 101–105.
37.
HigginsJPTAltmanDGGøtzschePC, et al. (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Clinical Research Ed.)343: d5928.
38.
Iglesias-GarcíaCToimil-IglesiasAAlonso-VillaMJ (2010) Pilot study of the efficacy of an educational programme to reduce weight, on overweight and obese patients with chronic stable schizophrenia. Journal of Psychiatric and Mental Health Nursing17(9): 849–851.
39.
ImbernonMSaponaroCHelmsHCC, et al. (2022) Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions. Cell Metabolism34(7): 1054–1063.e7.
40.
IshøyPLKnopFKBrobergBV, et al. (2017) Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: A randomized, placebo-controlled trial. Diabetes, Obesity & Metabolism19(2): 162–171.
41.
JarskogLFHamerRMCatellierDJ, et al. (2013) Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. The American Journal of Psychiatry170(9): 1032–1040.
42.
JoffeGTakalaPTchoukhineE, et al. (2008) Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: A 16-week randomized, double-blind, placebo-controlled trial. The Journal of Clinical Psychiatry69(5): 706–711.
43.
KhaityAMostafa Al-DarderyNAlbakriK, et al. (2023) Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: A systematic review and meta-analysis. Frontiers in psychiatry14: 1153648.
44.
KhazaalYFresardERabiaS, et al. (2007) Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. Schizophrenia Research91(1–3): 169–177.
45.
KimNWSongYMKimE, et al. (2016) Adjunctive α-lipoic acid reduces weight gain compared with placebo at 12 weeks in schizophrenic patients treated with atypical antipsychotics: A double-blind randomized placebo-controlled study. International Clinical Psychopharmacology31(5): 265–274.
46.
KoY-HJoeSHJungIK, et al. (2005) Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clinical Neuropharmacology28(4): 169–175.
47.
KwonJSChoiJSBahkWM, et al. (2006) Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial. The Journal of Clinical Psychiatry67(4): 547–553.
48.
LarsenJRVedtofteLJakobsenMSL, et al. (2017) Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: A randomized clinical trial. JAMA Psychiatry74(7): 719–728.
49.
LeeKAbrahamSCleaverR (2022) A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. General Hospital Psychiatry78: 58–67.
50.
LuyckxASLefebvrePJ (1971) Plasma insulin in reactive hypoglycemia. Diabetes20(6): 435–442.
51.
LuM-LLaneHYLinSK, et al. (2004) Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. The Journal of Clinical Psychiatry65(6): 766–771.
52.
LyuXDuJZhanG, et al. (2018) Naltrexone and bupropion combination treatment for smoking cessation and weight loss in patients with schizophrenia. Frontiers in Pharmacology9: 181.
53.
MarsoSPBainSCConsoliA, et al. (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine375(19): 1834–1844.
54.
MauriMSimonciniMCastrogiovanniS, et al. (2008) A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine. Pharmacopsychiatry41(1): 17–23.
55.
McKibbinCLPattersonTLNormanG, et al. (2006) A lifestyle intervention for older schizophrenia patients with diabetes mellitus: A randomized controlled trial. Schizophrenia Research86(1–3): 36–44.
56.
MelamedYStein-ReisnerOGelkopfM, et al. (2008) Multi-modal weight control intervention for people with persistent mental disorders. Psychiatric Rehabilitation Journal31(3): 194–200.
57.
MenzaMVreelandBMinskyS, et al. (2004) Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. The Journal of Clinical Psychiatry65(4): 471–477.
58.
MitchellAJVancampfortDSweersK, et al. (2013) Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—a systematic review and meta-analysis. Schizophrenia Bulletin39(2): 306–318.
59.
NickelMKNickelCMuehlbacherM, et al. (2005) Influence of topiramate on olanzapine-related adiposity in women: A random, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology25(3): 211–217.
60.
OlfsonMGerhardTHuangC, et al. (2015) Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry72(12): 1172–1181.
61.
PaeCUKimJJLeeKU, et al. (2003) Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: A pilot study. Human Psychopharmacology18(6): 453–456.
62.
PageMJMcKenzieJEBossuytPM, et al. (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Medicine18(3): e1003583.
63.
PatelKRCherianJGohilK, et al. (2014) Schizophrenia: Overview and treatment options. P&T: A Peer-Reviewed Journal for Formulary Management39(9): 638–645.
64.
PatinoLRStrawnJRAdlerCM, et al. (2025) A double-blind, placebo-controlled trial of exenatide for the treatment of olanzapine-related weight gain in obese and overweight adults. Journal of Affective Disorders382: 116–122.
65.
PendleburyJBusheCJWildgustHJ, et al. (2007) Long-term maintenance of weight loss in patients with severe mental illness through a behavioural treatment programme in the UK. Acta Psychiatrica Scandinavica115(4): 286–294.
66.
PillingerTMcCutcheonRAVanoL, et al. (2020) Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis. The Lancet. Psychiatry7(1): 64–77.
67.
PoyurovskyMPashinianAGil-AdI, et al. (2002) Olanzapine-induced weight gain in patients with first-episode schizophrenia: A double-blind, placebo-controlled study of fluoxetine addition. The American Journal of Psychiatry159(6): 1058–1060.
68.
PuZSunYJiangH, et al. (2021) Effects of berberine on gut microbiota in patients with mild metabolic disorders induced by olanzapine. The American Journal of Chinese Medicine49(8): 1949–1963.
69.
QiuYLiMZhangY, et al. (2022) Berberine treatment for weight gain in patients with schizophrenia by regulating leptin rather than adiponectin. Asian Journal of Psychiatry67: 102896.
70.
QureshiNAl-DossariDSSalemSO, et al. (2018) Antipsychotic medications and weight gain: etiologies, predictors and adverse clinical consequences. International Neuropsychiatric Disease Journal11(2): 1–19.
71.
RatliffJCPalmeseLBTonizzoKM, et al. (2012) Contingency management for the treatment of antipsychotic-induced weight gain: A randomized controlled pilot study. Obesity Facts5(6): 919–927.
72.
Rayyan – Intelligent Systematic Review (n.d.). Available at: https://www.rayyan.ai/ (accessed 7 December 2024).
73.
RoerigJLSteffenKJMitchellJE (2011) Atypical antipsychotic-induced weight gain: Insights into mechanisms of action. CNS Drugs25(12): 1035–1059.
74.
SabeMPillingerTKaiserS, et al. (2022) Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends. Neuroscience and Biobehavioral Reviews136: 104608.
75.
SabéMPallisKSolmiM, et al. (2023) Comparative effects of 11 antipsychotics on weight gain and metabolic function in patients with acute schizophrenia: A dose-response meta-analysis. The Journal of Clinical Psychiatry84(2): 22r14490.
76.
SavillM. (2020) Psychosocial/non-pharmacologic treatment of negative symptoms: Focus on efficacy. In: Managing negative symptoms of schizophrenia. Oxford University Press, pp. 87–106.
77.
SchultesBOltmannsKMKernW, et al. (2003) Modulation of hunger by plasma glucose and metformin. The Journal of Clinical Endocrinology and Metabolism88(3): 1133–1141.
78.
SiskindDBakerAArnautovskaU, et al. (2025) Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): A phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia. The Lancet. Psychiatry12(7): 493–503. doi:10.1016/S2215-0366(25)00129-4.
79.
SkrinarGSHuxleyNAHutchinsonDS, et al. (2005) The role of a fitness intervention on people with serious psychiatric disabilities. Psychiatric Rehabilitation Journal29(2): 122–127. doi:10.2975/29.2005.122.127.
80.
SmithRCMaayanLWuR, et al. (2018) Betahistine effects on weight-related measures in patients treated with antipsychotic medications: A double-blind placebo-controlled study. Psychopharmacology235(12): 3545–3558.
81.
SpineliLM (2022) A revised framework to evaluate the consistency assumption globally in a network of interventions. Medical Decision Making42(5): 637–648.
82.
StępnickiPKondejMKaczorAA (2018) Current concepts and treatments of schizophrenia. Molecules, 23(8): 2087.
83.
SugawaraNSagaeTYasui-FurukoriN, et al. (2018) Effects of nutritional education on weight change and metabolic abnormalities among patients with schizophrenia in Japan: A randomized controlled trial. Journal of Psychiatric Research97: 77–83.
84.
TangCChuaYCAbdinE, et al. (2021) Twenty-four week, randomized, double-blind, placebo-controlled trial of metformin for antipsychotic-induced weight gain in patients with first-episode psychosis: A pilot study. International Journal of Environmental Research and Public Health19(1): 137.
85.
TaveiraTHWuWCTschibeluE, et al. (2014) The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: A randomized double-blind placebo-controlled pilot study. Journal of Psychopharmacology28(4): 395–400.
86.
TekCRatliffJReutenauerE, et al. (2014) A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: Proof of concept. Journal of Clinical Psychopharmacology34(5): 608–612.
87.
UsherKParkTFosterK, et al. (2013) A randomized controlled trial undertaken to test a nurse-led weight management and exercise intervention designed for people with serious mental illness who take second generation antipsychotics. Journal of Advanced Nursing69(7): 1539–1548.
88.
VarleyCK (2009) Implications of marked weight gain associated with atypical antipsychotic medications in children and adolescents. JAMA302(16): 1811.
89.
VreelandBMinskySMenzaM, et al. (2003) A program for managing weight gain associated with atypical antipsychotics. Psychiatric Services54(8): 1155–1157.
90.
WangMTongJHZhuG, et al. (2012) Metformin for treatment of antipsychotic-induced weight gain: A randomized, placebo-controlled study. Schizophrenia Research138(1): 54–57.
91.
WeberMWyneK (2006) A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. Schizophrenia Research83(1): 95–101.
92.
WeidenPJMackellJAMcDonnellDD (2004) Obesity as a risk factor for antipsychotic noncompliance. Schizophrenia Research66(1): 51–57.
93.
WeizmanSShelefABloemhof BrisE, et al. (2021) A double-blind, placebo-controlled trial of bupropion add-on to olanzapine or risperidone in overweight individuals with schizophrenia. Journal of Clinical Psychopharmacology41(6): 629–631.
94.
WhicherCAPriceHCPhiriP, et al. (2021) The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trial. Diabetes, Obesity & Metabolism23(6): 1262–1271.
95.
WildingJPHBatterhamRLCalannaS, et al. (2021) Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine384(11): 989–1002.
96.
WuMKWangCKBaiYM, et al. (2007) Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatric Services58(4): 544–550.
97.
WuRRZhaoJPJinH, et al. (2008) Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: A randomized controlled trial. The Journal of the American Medical Association299(2): 185–193.
98.
WuRRJinHGaoK, et al. (2012) Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: A double-blind, randomized, placebo-controlled study. The American Journal of Psychiatry169(8): 813–821.
XiePShaoTLongY, et al. (2024) Orlistat for the treatment of antipsychotic-induced weight gain: an eight-week multicenter, randomized, placebo-controlled, double-blind trial. Lipids in Health and Disease23(1): 225.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
